Lymphocytic gastritis and associated small bowel disease: a diffuse lymphocytic gastroenteropathy?


Abstract

Aim – To investigate the natural history of lymphocytic gastritis (LG) and its relation to Helicobacter pylori infection and to coeliac disease using serology, duodenal biopsy and a small intestinal permeability test.

Method – Twenty two patients diagnosed as having LG between 1984 and 1994 were investigated by upper gastrointestinal endoscopy at which gastric and duodenal biopsy specimens were taken for histological assessment and immunohistology. Serum was collected for measurement of anti-H pylori, anti-gliadin and anti-endomysial antibodies. A lactulose/mannitol absorption test was performed within one week of endoscopy. Control groups were studied by histology, serology and permeability tests.

Results – Three patients had been recently diagnosed as having LG while 15 still had the condition after a mean of 13.9 (range two to 38) months. LG involved the antrum alone in three patients, antrum and body in seven, body alone in six, and gastric remnant in two. Gastroduodenal intraepithelial lymphocytes (IELs) were T cells and predominantly of T suppressor (CD8) type. Duodenal IELs were increased compared to age/sex matched controls with chronic gastritis. Four patients had duodenal villous atrophy. Four patients no longer had LG after a mean of 29.3 (10–70) months but had increased gastroduodenal IELs. H pylori was present in four (22%) of 18 patients with LG but H pylori serology was positive in 11 (61%) of 18. There was no difference in seropositivity when compared with age/sex matched controls with dyspepsia. Eleven of 20 patients with LG tested had abnormal lactulose/mannitol absorption (v none of 22 controls with chronic gastritis). Four patients with LG, all with villous atrophy, were seropositive for IgA endomysial antibody.

Conclusions – The persistence of LG with time, the association with increased duodenal IELs and abnormal small intestinal permeability suggests LG may be a manifestation of a diffuse lymphocytic gastroenteropathy related to sensitivity to gluten or some other agent.

Lymphocytic gastritis is the histological counterpart of the macroscopic entity, varioliform gastritis.1,2 It is found in approximately 1% of gastric biopsy specimens from dyspeptic patients3 and is characterised by an accumulation of lymphocytes in the surface and foveolar epithelium (fig 1).2 The normal stomach is devoid of intraepithelial lymphocytes (IELs) while in Helicobacter pylori associated chronic gastritis between four and seven lymphocytes per 100 epithelial cells are found.12 The diagnostic threshold for lymphocytic gastritis is usually taken as greater than 25 IELs per 100 cells.12 Endoscopically, there are enlarged rugal folds bearing nodular erosions principally involving the body of the stomach though in some cases of histological lymphocytic gastritis the endoscopic appearances may be normal.12

Little is known of the aetiology or natural history of lymphocytic gastritis. It has been attributed to an atypical response to H pylori infection.2 However, while many patients are seropositive to the micro-organism, its presence is not usually confirmed histologically.5 It has also been suggested that lymphocytic gastritis may be a manifestation of coeliac disease. In one study of 22 patients with coeliac disease half had lymphocytic gastritis.13 The IELs in the stomach and small bowel were positive for MT-1, indicative of T cell infiltration.6 Two studies have reported that lymphocytic gastritis resolves after about two years, suggesting that the condition is transient.7 We have investigated the natural history of lymphocytic gastritis and explored further the relation with H pylori infection and small intestinal disease.

Methods

Thirty six patients with a histological diagnosis of lymphocytic gastritis made between 1984 and 1994 were approached for investigation. Three were recently diagnosed cases; 19 other patients agreed to undergo repeat endoscopy and biopsy. Prior to endoscopy, a full history was taken and clinical examination performed. Venous blood was taken for H pylori serology and endomysial and gliadin antibody studies. Serum samples were stored at −20°C until assayed. A lactulose/mannitol absorption test for the assessment of small intestinal permeability was performed within one week of the endoscopy. The study was approved by the local research ethics committee.

Keywords: Lymphocytic gastritis, intraepithelial lymphocytes, small intestinal permeability, coeliac disease, Helicobacter pylori.
with lymphocytic gastritis, snap frozen in liquid nitrogen at \(-80^\circ\text{C}\) and sectioned. Immunostaining was performed using a three step immunoperoxidase technique. The following monoclonal antibodies (all from Dako, High Wycombe, UK) were used: anti-CD3 (pan T cell marker) at a 1 in 50 dilution; anti-CD22 (pan B cell) at a 1 in 100 dilution; anti-CD4 (T helper (CD4) cell) at a 1 in 8 dilution; and anti-CD8 (T cytotoxic-suppressor (CD8) cell) at a 1 in 25 dilution. Frozen tissue from four dyspeptic patients with normal gastric and duodenal mucosa on routine histology were used as controls.

**H pylori serology**

Serum samples from all 22 test subjects were assayed for *H pylori* IgG antibodies by an in house enzyme linked immunosorbent assay. A control group for the prevalence of positive *H pylori* serology comprised 22 age/sex matched subjects who presented consecutively to our open access endoscopy clinic with a history of dyspepsia.

**Glutaminase and endomyosal antibodies**

Serum IgA, IgG and IgM anti-gliadin antibodies (AGA) were measured in all 22 test subjects using a previously described method. The control group comprised 22 healthy subjects used by Mwantembe and Ferguson (unpublished data). Serum samples were also assayed for IgA endomyosal antibodies (EMA) using a method described previously.

**Lactulose/mannitol absorption**

Small intestinal permeability was determined using this standard non-invasive technique in 20 subjects. The normal urinary lactulose/mannitol ratio is 0-07 or lower. A group of 22 patients with a similar age/sex distribution

***Table 1 Clinical details of patients with current and previous lymphocytic gastritis***

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Interval (months)</th>
<th>OGD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current lymphocytic gastritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>40</td>
<td>F</td>
<td>30</td>
<td>VG</td>
</tr>
<tr>
<td>2</td>
<td>68</td>
<td>M</td>
<td>15</td>
<td>AE</td>
</tr>
<tr>
<td>3</td>
<td>59</td>
<td>M</td>
<td>15</td>
<td>PG</td>
</tr>
<tr>
<td>4</td>
<td>61</td>
<td>F</td>
<td>38</td>
<td>N</td>
</tr>
<tr>
<td>5</td>
<td>44</td>
<td>M</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>6</td>
<td>24</td>
<td>M</td>
<td>22</td>
<td>N</td>
</tr>
<tr>
<td>7</td>
<td>88</td>
<td>F</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>8</td>
<td>26</td>
<td>F</td>
<td>2</td>
<td>VG</td>
</tr>
<tr>
<td>9</td>
<td>78</td>
<td>F</td>
<td>2</td>
<td>N</td>
</tr>
<tr>
<td>10</td>
<td>70</td>
<td>M</td>
<td>2</td>
<td>HDU</td>
</tr>
<tr>
<td>11</td>
<td>47</td>
<td>F</td>
<td>2</td>
<td>VG</td>
</tr>
<tr>
<td>12</td>
<td>55</td>
<td>M</td>
<td>21</td>
<td>N</td>
</tr>
<tr>
<td>13</td>
<td>39</td>
<td>M</td>
<td>9</td>
<td>N</td>
</tr>
<tr>
<td>14</td>
<td>45</td>
<td>M</td>
<td>15</td>
<td>VG</td>
</tr>
<tr>
<td>15</td>
<td>60</td>
<td>F</td>
<td>31</td>
<td>GE</td>
</tr>
<tr>
<td>16</td>
<td>55</td>
<td>M</td>
<td>-</td>
<td>VG</td>
</tr>
<tr>
<td>17</td>
<td>69</td>
<td>F</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>18</td>
<td>59</td>
<td>F</td>
<td>-</td>
<td>N</td>
</tr>
<tr>
<td>Previous lymphocytic gastritis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>69</td>
<td>M</td>
<td>13</td>
<td>N</td>
</tr>
<tr>
<td>20</td>
<td>23</td>
<td>M</td>
<td>70</td>
<td>N</td>
</tr>
<tr>
<td>21</td>
<td>39</td>
<td>F</td>
<td>24</td>
<td>N</td>
</tr>
<tr>
<td>22</td>
<td>66</td>
<td>M</td>
<td>10</td>
<td>VG</td>
</tr>
</tbody>
</table>

* Time interval from original diagnosis of lymphocytic gastritis.

OGD = oesophagogastrroduodenoscopy; N = normal; VG = va-roiform gastritis; HDU = healed duodenal ulcer; AE = antral erythema; PG = partial gastrectomy; GE = gastroenterostomy.

**Histology**

At endoscopy, a single biopsy specimen was taken from the second part of the duodenum, gastric antrum and body using standard biopsy forceps. Specimens were fixed in 10% buffered formalin, embedded in paraffin wax, and stained with haematoxylin and eosin. A modified Giemsa stain was used to detect *H pylori*. The haematoxylin and eosin stained sections were examined at x 400 magnification and the number of IELs and epithelial cell nuclei in an uninterrupted length of surface and foveolar epithelium were counted. At least 500 epithelial cells were counted and the results expressed as lymphocytes per 100 epithelial cells. For the purpose of comparison we took biopsy specimens of the same sites from age/sex matched patients undergoing endoscopy for dyspeptic symptoms, and found to have *H pylori* associated gastritis.

**Immunohistology**

Additional duodenal and gastric biopsy specimens were taken as above from seven patients...
undergoing routine diagnostic endoscopy, and found to have chronic gastritis (with or without *H pylori* infection), were used as controls.

STATISTICAL ANALYSIS

For comparison of unpaired non-parametric data the Mann-Whitney U test was used. A *p* value less than 0.05 was regarded as significant.

Results

ENDOSCOPY

Of those patients with current lymphocytic gastritis, endoscopy was normal in nine. One showed erythema with thickening of the antral mucosal folds, while five had multiple small elevated plaques with superficial ulceration in the body and antrum. One of these had a healing ulcer in the duodenal cap. One patient had a partial gastrectomy and another had a gastroenterostomy for peptic ulcer disease, while another had a healed duodenal ulcer. Of the four patients who no longer had lymphocytic gastritis, three were normal and one still had the typical varioliform appearance (table 1).

HISTOLOGY

Three patients had recently been diagnosed as having lymphocytic gastritis. Fifteen of the remaining 19 patients had persisting lymphocytic gastritis a mean of 13-9 months (range two to 38) after the original diagnosis. This group of 18 patients will be referred to as patients with current lymphocytic gastritis (table 1). The gastric antrum and body were involved in seven patients, antrum alone in three, body alone in six, and gastric remnant in two. In patients with current lymphocytic gastritis the median IEL count in the antrum was 27.5% (interquartile range 23-31) and was 32.5% (28-38.5) in the body. There was no significant difference between the antral and body IEL counts. Duodenal (second part) histology was normal in 14 patients. Three patients had severe villous atrophy of the duodenum and one patient had marked villous atrophy in a jejunal biopsy. The median duodenal IEL count in the patients with current lymphocytic gastritis was 19% (14-6-22.8).

Four patients no longer had lymphocytic gastritis after a mean of 29-3 months (range 10-70) and will be referred to as patients with previous lymphocytic gastritis. In patients with previous lymphocytic gastritis the gastric and duodenal mucosal sections were described as histologically normal. However, antral and body IEL counts were 17% (8-19) and 14% (14-20), respectively. The median duodenal IEL count in patients with previous lymphocytic gastritis was 17% (14-20). The antral, body and duodenal IEL counts in all patients with lymphocytic gastritis (current and previous) were significantly higher than in the controls (control values: duodenum, 9.5% (7-11) (*p*<0.001); antrum, 7% (5-3-8) (*p*<0.001); body, 6% (3-3-8) (*p*<0.001)).

 Adequate biopsy specimens from both antrum and corpus were available from the initial diagnostic endoscopy in only 11 patients for comparison with the follow up biopsy specimens. Gastric IELs were counted in these paired biopsy specimens (seven with current lymphocytic gastritis and four with previous lymphocytic gastritis). The initial and follow up counts are shown in fig 2. There was a significant (*p* = 0.0005) fall in IEL counts with time.

H* pylori* HISTOLOGY AND SEROLOGY

*H pylori* was found on histology in four of 18 patients with current lymphocytic gastritis. One patient found to have duodenal villous atrophy had been *H pylori* positive in the past and had been treated, six months previously, with a two week course of anti-helicobacter triple therapy comprising tetracycline, bismuth complex and metronidazole. He is currently negative for *H pylori* histologically. Furthermore, *H pylori* serology was also negative. None of the four patients with previous gastritis were *H pylori* positive. Eleven of the 18 patients with current lymphocytic gastritis were seropositive, six were seronegative, and one was borderline. Three of four patients with previous lymphocytic gastritis tested were seronegative (table 2). Seventeen of 22 random dyspeptic control subjects were seropositive, one was borderline and four were seronegative for *H pylori*. The difference in seropositivity between patients with lymphocytic gastritis and the control group was not statistically significant.

IMMUNOHISTOLOGY

Seven patients with current lymphocytic gastritis were studied. The duodenal and gastric IELs were virtually all positive for CD3. There was no positive staining of IELs for CD22. The IELs were predominantly of CD8+ T cytotoxic suppressor type, the remainder being CD4+ T cells. In order to determine whether there was a shift in the proportion of CD8 IELs
the CD8/CD4 ratios were calculated (table 3). There was no significant difference in gastroduodenal CD8/CD4 ratios between patients with lymphocytic gastritis and control subjects.

LACTULOSE/MANNITOL ABSORPTION
Nine of 17 patients with current lymphocytic gastritis, including three patients with villous atrophy, had abnormal small intestinal permeability. Two out of three patients with previous lymphocytic gastritis tested had abnormal lactulose/mannitol absorption (table 2). None of the 22 control subjects (median age 53 (range 21–73) years; 13 females) had abnormal small intestinal permeability (mean (SD), 0.327 (0.021), range 0.01–0.07).

RESPONSE TO GLUTEN WITHDRAWAL
Two of the four patients with lymphocytic gastritis and villous atrophy were placed on a gluten

Figure 3 Duodenal (second part) biopsy specimens from a patient with lymphocytic gastritis and villous atrophy before (left) and after (right) three months of treatment with a gluten free diet.
Lymphocytic gastritis and small bowel disease

Table 4 Serum levels of anti-gliadin antibodies in patients with lymphocytic gastritis and age/sex matched controls

<table>
<thead>
<tr>
<th>Group</th>
<th>IgA (mg/ml)</th>
<th>IgG (mg/ml)</th>
<th>IgM (mg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n=23)</td>
<td>7 (2-35)</td>
<td>27 (4-60)</td>
<td>37 (15-86)</td>
</tr>
<tr>
<td>Lymphocytic gastritis (n=22)</td>
<td>8 (3-49)</td>
<td>32 (9-85)</td>
<td>46 (9-131)</td>
</tr>
<tr>
<td>p=0.15</td>
<td>p=0.015</td>
<td>p=0.004</td>
<td>p=0.033</td>
</tr>
</tbody>
</table>

There was no difference between the two groups when assayed for serum IgA and IgM. However, serum IgG AGA is increased in lymphocytic gastritis.

free diet. Both patients showed evidence of clinical and biochemical improvement. One patient who had varioliform gastritis at presentation, underwent a repeat endoscopy three months after gluten withdrawal. The endoscopic appearances were improved; there were no superficial erosions but the gastric mucosal folds remained slightly thickened. There was also a marked improvement in villous morphology in the duodenum (fig 3) but no change in the IEL counts (26–29%). However, there was a non-significant reduction in the antral and body mucosa IEL counts from 39 to 32% and from 46 to 32%, respectively.

GLIADIN AND ENDOMYSIAL ANTIBODIES
Fourteen of 18 patients with current lymphocytic gastritis were seronegative for IgA EMA. The four patients with duodenal or jejunal villous atrophy were seropositive. There was no significant difference between patients with current or previous lymphocytic gastritis compared with the control group when assayed for IgA and IgM AGA. Subjects with lymphocytic gastritis had increased serum IgG AGA (table 4). However, if patients with villous atrophy were excluded from analysis no difference was observed.

Discussion
Previous studies have suggested that lymphocytic gastritis resolves after about two years. While our results show that there is a reduction in gastric IEL counts over time (fig 2), three patients had the condition up to three years after the original diagnosis. Furthermore, patients with “resolved” or previous lymphocytic gastritis, which appears normal on routine histological examination, have significantly higher gastric mucosal IEL counts than controls. Thus, the resolution is a lowering of the number of IELs below the diagnostic cut off level of 25% and not a return to normal. This suggests that the increased IELs in inflamed, albeit in some cases at a lower level than that required for a diagnosis of lymphocytic gastritis, is a persistent phenomenon. We confirm that the IELs are T cells and that the majority are of T suppressor type (CD8). As in previous studies we have found that the histological distribution of lymphocytic gastritis varies throughout the stomach. The antrum and body can be involved independently or together. However, the entire gastric mucosa in patients with lymphocytic gastritis is histologically abnormal. While the IELs are not present in some areas in sufficient numbers for a diagnosis of lymphocytic gastritis, they are higher than in controls. We also confirm that lymphocytic gastritis varies in its endoscopic appearance. It can take on the classic diffused varioliform gastritis but the antral folds alone may appear red and thickened. In a minority of patients the endoscopic appearances may be normal.

In this study four patients with lymphocytic gastritis had severe villous atrophy consistent with coeliac disease. We have also found that patients with lymphocytic gastritis and normal villous architecture have increased IEL numbers in their duodenal mucosa. While an increased prevalence of lymphocytic gastritis has been reported in coeliac disease, a previous study of patients with lymphocytic gastritis did not detect any small bowel abnormality on standard histological examination. Increased small intestinal IEL counts are present in patients with treated coeliac disease following gluten challenge, dermatitis herpetiformis, first degree relatives of patients with coeliac disease, and those with low grade small intestinal enteropathy. The finding of increased IEL numbers in the duodenal mucosa and, in two cases, the beneficial effects of gluten withdrawal, lend some support to the hypothesis that lymphocytic gastritis is another manifestation of a gluten related enteropathy. The finding of abnormal small intestinal permeability in patients with current and previous lymphocytic gastritis without histological evidence of villous atrophy is of interest. Only one patient (case 16) was taking non-steroidal anti-inflammatory drugs and his permeability test was normal. Our results suggest that lymphocytic gastritis per se is associated with impaired small bowel function. This finding should prompt a re-appraisal of the reported link between lymphocytic gastritis and a protein losing gastropathy which was first recognised by Crampton et al. These authors described two patients in a protein losing state in whom there were thickened gastric folds with histological features of lymphocytic gastritis but no histological evidence of Ménétrier’s disease. Duodenal biopsy specimens showed a marked increase in IEL numbers. Further cases of lymphocytic gastritis associated with hypoprothrominaemia have been described subsequently. It is also noteworthy that one patient in a series with abnormal small intestinal absorption, who did not have histological evidence of coeliac disease using standard histological techniques, had multiple elevated gastric erosions at endoscopy.

The anti-endomysial and anti-gliadin results in our patients, apart from the positive EMA in the two patients with villous atrophy, are not surprising. It is becoming evident that antibodies to gluten or its components are epitope phenomena that reflect small bowel mucosal damage in response to gluten. Abnormal small intestinal permeability occurs in the presence of normal jejunal histology and morphology in dermatitis herpetiformis and in relatives of patients with coeliac disease. Furthermore, it has been demonstrated to precede the development of coeliac disease. Latent gluten sensitive enteropathy occurs...
in apparently healthy and first degree relatives of patients with coeliac disease. Differing degrees of sensitivity to gliadin are believed to account for the geographical variation in the incidence of coeliac disease and the spectrum of histological changes from complete villous atrophy to normal jejunal mucosa.\textsuperscript{92-27} Inappropriate immune reactions to gliadin occur in the mouth\textsuperscript{28} and the rectum\textsuperscript{29} and recently an association between lymphocytic colitis and coeliac disease has been described.\textsuperscript{30} Therefore gastric mucosal involvement is not unexpected. Coeliac disease is associated with an increased incidence of gastritis and abnormal gastric function which has previously been attributed to an autoimmune gastritis.\textsuperscript{31-35} However, the incidence of autoimmune gastritis has been found to be low in coeliac disease\textsuperscript{34} whereas gastric mucosal IEL numbers are increased.\textsuperscript{35,36} Co-existent lymphocytic gastritis may account, in part, for these abnormalities.

Using serology, we have found no difference in the prevalence of \textit{H pylori} antibodies in patients with lymphocytic gastritis compared with dyspeptic controls. The relatively low prevalence of the organism on histology\textsuperscript{1} when compared with the usual chronic (type B) gastritis, and the discrepancy between the histological and serological \textit{H pylori} status in patients with lymphocytic gastritis is consistent with a previous study.\textsuperscript{2} However, a negative histological result might not necessarily mean that infection is absent. False negative results could be explained by inadequacies in technique—that is, the bacteria could be present in very small numbers and not recognised in the sections. Alternatively, they may have adopted the coccoïd form in response to the hostile environment brought about by the mucosal inflammatory response. Sensitive methods of detection such as in situ hybridisation or a polymerase chain reaction technique would clarify this point. While it is possible that lymphocytic gastritis is a manifestation of an effective, but unusual, host immune response to \textit{H pylori}, it may be completely unrelated to infection. It is certainly apparent that in most cases the process persists in an active form in the absence of \textit{H pylori} infection. However, an alternative explanation is that \textit{H pylori} infection triggers an immunopathological process in the gastric mucosa of predisposed individuals, possibly by the enhanced expression of class II HLA,\textsuperscript{38} in much the same way as latent gluten enteropathy could be unmasked by intestinal infection and lead to its presentation as overt adult onset coeliac disease.

In conclusion, we have found that gastric mucosal IELs remain persistently elevated in subjects with lymphocytic gastritis, refuting previous suggestions that the disease is transient. The finding of duodenal villous atrophy in four patients, and the presence of increased duodenal IEL numbers and abnormal small intestinal permeability in other patients, leads one to speculate that lymphocytic gastritis represents part of a diffuse lymphocytic gastroenteropathy which varies in its expression from site to site. Thus, coeliac disease represents a primary small intestinal disorder which is accompanied by intraepithelial lymphocytosis in the stomach, while lymphocytic gastritis is primarily accompanied by intraepithelial lymphocytosis and functional disturbances in the small intestine. On rare occasions, coeliac disease and fully developed (varioliform) lymphocytic gastritis co-exist. Whether these two conditions represent abnormal immune reactions to a common antigen related to gluten or to totally different antigens awaits further investigation. Likewise, the relation of lymphocytosis in the large intestine to coeliac disease and lymphocytic gastritis requires further study. It is possible that lymphocytic colitis is another manifestation of a mucosal immune response to luminal antigen, which in this instance is maximally expressed in the large intestine. A comparison of HLA status and the antigen responsiveness of gastrointestinal lymphocytes in patients with lymphocytic gastritis, lymphocytic colitis and coeliac disease would add greatly to our understanding of the inter-relations between these intriguing conditions.

We would like to thank Professor A Ferguson and Mr N Anderson for performing the anti-gliadin assays.

Lymphocytic gastritis and small bowel disease


Lymphocytic gastritis and associated small bowel disease: a diffuse lymphocytic gastroenteropathy?

D A Lynch, G M Sobala, M F Dixon, A Gledhill, P Jackson, J E Crabtree and A T Axon

doi: 10.1136/jcp.48.10.939

Updated information and services can be found at:
http://jcp.bmj.com/content/48/10/939

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/